Profile picture

Professor Jong-Chan Youn

Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul (Korea (Republic of))
Membership: ESC Professional Member HFA Member
Follow
Biography
Dr. Jong-Chan Youn is a Professor at Seoul St. Mary's Hospital and earned his medical degree and Ph.D. from Yonsei University College of Medicine. He conducted cardiovascular immunology and senescent T cell research as a postdoctoral researcher at KAIST's Immunology Lab. Dr. Youn's clinical expertise covers hypertension, dyslipidemia, and advanced heart failure, and he has published over 60 peer-reviewed articles in prestigious journals. He is an Assistant Editor of the 'Korean Circulation Journal' and an Associate Editor of the 'International Journal of Heart Failure'. Dr. Youn is an active member of several academic societies, including the Korean Society of Cardiology and the International Society for Heart and Lung Transplantation. He has received research grants as a principal investigator from various academic societies and the Korean Ministry of Science, ICT & Future Planning.
Logo ESC

Contributor content

Temporal Trends in HF Outcomes
Presentation
Temporal Trends in HF Outcomes
Evaluating the clinical consequences of atrial fibrillation in asian women with breast cancer
Presentation
Evaluating the clinical consequences of atrial fibrillation in asian women with breast cancer
Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure on replacement therapy
Presentation
Angiotensin receptor-neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure on replacement therapy
Temporal trends and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study
Presentation
Temporal trends and clinical characteristics of variant versus wild-type transthyretin amyloid cardiomyopathy in Asian population: the Korean nationwide cohort study
A budget impact analysis of empagliflozin for heart failure patients with full spectrum of ejection fraction in South Korea
Presentation
A budget impact analysis of empagliflozin for heart failure patients with full spectrum of ejection fraction in South Korea
Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the  whole spectrum of ejection fraction
Presentation
Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction
CD4+CD57+ T cells are increased and associated with clinical outcome in patients with acute heart failure
Presentation
CD4+CD57+ T cells are increased and associated with clinical outcome in patients with acute heart failure

ESC 365 is supported by